Literature DB >> 20071147

DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication.

Victor Peralta1, Maria S Campos, Elena Garcia de Jalon, Manuel J Cuesta.   

Abstract

OBJECTIVE: To examine the prevalence, psychometric validity and response to antipsychotic drugs of DSM-IV catatonia signs and criteria in patients with a first-episode psychotic disorder.
METHODS: Two-hundred antipsychotic-naive patients with a DSM-IV nonaffective psychosis were assessed for catatonia signs and criteria using the Modified Rogers Scale, and the psychometric validity of the 12 DSM-IV catatonia signs and diagnostic criteria was examined. Treatment response of catatonia was assessed in 173 patients who completed one-month trial with haloperidol (n=23), risperidone (n=93) or olanzapine (n=57).
RESULTS: Sixty-two patients (31%) endorsed at least one catatonia sign and 24 (12%) met DSM-IV criteria for catatonia. DSM-IV catatonia signs showed an excellent convergent validity (r>0.8) with other rating scales, and DSM-IV criteria showed moderate to fair concordance with other criteria (kappa from 0.57 to 0.77). The total number of signs reflected catatonia severity and demonstrated excellent diagnostic performance against alternative diagnostic criteria. The presence of at least any three signs accurately identified patients with catatonia. Three catatonia domains were identified (hyperkinesia, volitional and hypokinesia), which showed a different association pattern with external variables. Overall, catatonia ratings were particularly related to both dyskinesia and disorganization symptoms and lacked diagnostic specificity for schizophrenia. Patients with catatonia responded well to antipsychotic medication irrespective of the type of antipsychotic drug used, although treatment response was dependent upon the remission of psychotic symptoms.
CONCLUSIONS: These results may inform the DSM-V development on diagnosis and classification of catatonia, and indicate that catatonia signs and syndromes are highly responsive to antipsychotic drugs. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20071147     DOI: 10.1016/j.schres.2009.12.023

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  17 in total

1.  Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.

Authors:  Andrew Francis; Max Fink; Francisco Appiani; Aksel Bertelsen; Tom G Bolwig; Peter Bräunig; Stanley N Caroff; Brendan T Carroll; Andrea Eugenio Cavanna; David Cohen; Olivier Cottencin; Manuel J Cuesta; Jessica Daniels; Dirk Dhossche; Gregory L Fricchione; Gabor Gazdag; Neera Ghaziuddin; David Healy; Donald Klein; Stephanie Krüger; Joseph W Y Lee; Stephan C Mann; Michael Mazurek; W Vaughn McCall; William W McDaniel; Georg Northoff; Victor Peralta; Georgios Petrides; Patricia Rosebush; Teresa A Rummans; Edward Shorter; Kazumasa Suzuki; Pierre Thomas; Guillaume Vaiva; Lee Wachtel
Journal:  J ECT       Date:  2010-12       Impact factor: 3.635

Review 2.  Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis.

Authors:  Marco Solmi; G Giorgio Pigato; Beatrice Roiter; Argentina Guaglianone; Luca Martini; Michele Fornaro; Francesco Monaco; Andrè F Carvalho; Brendon Stubbs; Nicola Veronese; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

3.  Brief episodes of non-specific psychosis later diagnosed as periodic catatonia.

Authors:  Victor Mark Tang; Helen Park
Journal:  BMJ Case Rep       Date:  2016-11-22

Review 4.  Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro)Psychiatric Disorders.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

5.  Cortical Contributions to Distinct Symptom Dimensions of Catatonia.

Authors:  Dusan Hirjak; Katharina M Kubera; Georg Northoff; Stefan Fritze; Alina L Bertolino; Cristina E Topor; Mike M Schmitgen; Robert C Wolf
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 6.  [Pharmacotherapy of psychiatric acute and emergency situations: General principles].

Authors:  T Messer; F-G Pajonk; M J Müller
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

Review 7.  Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.

Authors:  Michael W Huang; Roger Carl Gibson; Mahesh B Jayaram; Stanley N Caroff
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

8.  Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs.

Authors:  Victor Peralta; Lucía Moreno-Izco; Ana Sanchez-Torres; Elena García de Jalón; Maria S Campos; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2012-12-18       Impact factor: 9.306

Review 9.  [The sensorimotor domain in the research domain criteria system: progress and perspectives].

Authors:  Dusan Hirjak; Stefan Fritze; Georg Northoff; Katharina M Kubera; Robert Christian Wolf
Journal:  Nervenarzt       Date:  2021-06-11       Impact factor: 1.214

Review 10.  [Psychopharmacotherapy in emergency medicine].

Authors:  A Wolf; M J Müller; F-G B Pajonk
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-11       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.